Zusammenfassung
Die Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) gehört zu den häufigsten psychischen Störungen im Kindes- und Jugendalter. Teil einer multimodalen Therapie der ADHS ist häufig auch die medikamentöse Behandlung. Der selektive Noradrenalin-Wiederaufnahmehemmer Atomoxetin ist eine wirksame und gut verträgliche medikamentöse Behandlungsoption bei ADHS.
Summary
Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common psychiatric disorders in childhood and adolescence. Medication is often one component of a multi-modal treatment plan. Atomoxetine, a selective noradrenaline reuptake inhibitor is an effective and well-tolerated treatment option for patients with ADHD.
Key words
Atomoxetine - attention-deficit/hyperactivity disorder - ADHD - hyperkinetic disorder - norepinephrine reuptake inhibitor
Literatur
-
1
Adler LA, Spencer TJ, Milton DR, Moore RJ, Michelson D.
Long-term, open label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis.
J Clin Psychiatry.
2005;
66
294-299
-
2 American Academy of Child and Adolescent Psychiatry (AACAP) .Guidelines pocketcard. Managing attention-deficit/hyperactivity disorder. Version 2.0. American Academy of Child and Adolescent Psychiatry, Washington D. C. 2004 (Internet: www.aacap.org/clinical/parameters/pocket cards/pocket1.htm)
-
3
Becker K, Wehmeier PM.
Atomoxetin zur Behandlung der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörungen (ADHS).
PsychoNeuro.
2003;
10
472-476
-
4 Becker K, Wehmeier PM, Schmidt MH. Das noradrenerge Transmittersystem bei ADHS. Grundlagen und Bedeutung für die Therapie. Stuttgart: Georg Thieme 2005
-
5
Buitelaar JK, Danckaerts M, Gillberg C, Zuddas A, Becker K, Bouvard M, Fagan J, Gadoros J, Harpin V, Hazell P, Johnson M, Lerman-Sagie T, Soutullo CA, Wolanczyk T, Zeiner P, Fouche DS, Krikke-Workel J, Zhang S, Michelson D.
Atomoxetine International Study Group. A prospective, multi-center, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD.
European Child and Adolescent Psychiatry.
2004;
13
249-257
-
6 Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie u.a. .Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter. Köln, Deutscher Ärzte Verlag, (Internet: www.uni-duesseldorf.de/WWW/AWMF/ll/kjpp-019.htm) 2000
-
7 Eli Lilly & Company .Strattera™ (atomoxetine HCl). (Amerikanische Fachinformation) Eli Lilly and Company, Indianapolis, Dezember (Internet: pi.lilly.com/us/strattera-pi.pdf) 2004
-
8
Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ.
Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
Pediatrics.
2004;
14
e1-e8
-
9 Lilly Deutschland. Fachinformation Strattera®, (Internet: www.fachinfo.de/data/fi/pdf/00/87/008758.pdf) 2005
-
10 Michelson D. Results from a double-blind study of atomoxetine, OROS methylphenidate, and placebo. Scientific Proceedings of the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP). Washington D. C. 2004
-
11
Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D.
Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.
Am J Psychiatry.
2002;
159
1896-1901
-
12
Michelson D, Buitelaar JK, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, Faries DE, Zhang S, Biederman J.
Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study.
J Am Acad Child Adolesc Psychiatry.
2004;
43
896-904
-
13
Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D.
Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
J Am Acad Child Adolesc Psychiatry.
2005;
44
240-248
-
14
Thomason C, Michelson D.
Atomoxetine: treatment of attention deficit hyperactivity disorder: beyond stimulants.
Drugs of Today.
2004;
40
465-473
-
15
Wernicke JF, Kratochvil CJ.
Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.
J Clin Psychiatry.
2002;
63
50-55
Korrespondenzadresse:
Dr. med. Katja Becker
Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Zentralinstitut für Seelische Gesundheit
Postfach 12 21 20
68072 Mannheim
Email: katja.becker@zi-mannheim.de
